Zymeworks (ZYME) Stock Price, News & Analysis

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ZYME shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZYME, but not buy additional shares or sell existing shares.
View ZYME analyst ratings or view top-rated stocks.

1 equities research analysts have issued 1 year price targets for Zymeworks' stock. Their ZYME share price targets range from $8.00 to $19.00. On average, they predict the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 69.9% from the stock's current price.
View analysts price targets for ZYME or view top-rated stocks among Wall Street analysts.

Zymeworks' stock was trading at $10.39 at the beginning of 2024. Since then, ZYME shares have decreased by 15.0% and is now trading at $8.83.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ZYME earnings forecast.

Zymeworks will be holding an earnings conference call on Thursday, May 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Zymeworks Inc. (NYSE:ZYME) posted its earnings results on Wednesday, March, 6th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.19. The business earned $16.93 million during the quarter, compared to the consensus estimate of $18.32 million. Zymeworks had a negative trailing twelve-month return on equity of 26.20% and a negative net margin of 156.12%.

Invesco Russell 2000 Dynamic Multifactor ETF holds 165,345 shares of ZYME stock, representing 0.41% of its portfolio.

9 employees have rated Zymeworks Chief Executive Officer Ali Tehrani on Glassdoor.com. Ali Tehrani has an approval rating of 100% among the company's employees. This puts Ali Tehrani in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Zymeworks to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group (JE), PayPal (PYPL), Alibaba Group (BABA), Cronos Group (CRON), CRISPR Therapeutics (CRSP) and Tesla (TSLA).

Zymeworks (ZYME) raised $65 million in an initial public offering (IPO) on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity served as the underwriters for the IPO and Cormark Securities was co-manager.

Zymeworks' stock is owned by many different institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.20%) and AlphaMark Advisors LLC (0.00%). Insiders that own company stock include Ali Tehrani, Christopher Astle, Ecor1 Capital, Llc, Kenneth Galbraith, Neil A Klompas, Neil Josephson and Paul Andrew Moore.
View institutional ownership trends.

Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.